Last reviewed · How we verify
NCT06190847
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
trial testing regular chemoradiotherapy in Esophageal Squamous Cell Carcinoma in 97 participants. Currently enrolling.
1 July 2026
Quick facts
| Lead sponsor | Anhui Provincial Hospital |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 97 |
| Start date | 1 July 2023 |
| Primary completion | 1 July 2026 |
| Estimated completion | 1 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- regular chemoradiotherapy
Conditions studied
- Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →
- Chemoradiotherapy — all drugs for Chemoradiotherapy →
- Initial Inoperable — all drugs for Initial Inoperable →
Sponsor
Anhui Provincial Hospital
Who can join
Adults 18 to 85, any sex, with Esophageal Squamous Cell Carcinoma or Chemoradiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Esophageal cancer accounts for more than half of the world, seriously affecting people's health in China. 95% patients are squamous cell carcinoma. Surgery is the preferred treatment for early and middle stage esophageal cancer, but patients with clinical stage T4b or other surgical contraindications have no surgical opportunity. In recent years, radical chemoradiotherapy has played a key role in the treatment of local advanced esophageal cancer with some poor predicting biomarkers. Oral bacteria may play a pathogenic role in cancer and other chronic diseases by producing chemical carcinogens and inflammatory factors through direct metabolism. A large number of studies have also suggested that tooth loss and poor oral hygiene are closely related to upper digestive tract cancer, indicating the possible role of oral microorganisms in the occurrence and development of upper digestive tract cancer, and saliva is the main source of oral flora colonization. Therefore, it is worth further research to explore the interaction between microbial metabolism imbalance and radiotherapy in patients with esophageal cancer. In summary, we intend to conduct a prospective cohort study to explore the role of salivary microbes in radiotherapy in patients with initially inoperable patients with local advanced esophageal cancer.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Role of the Microbiome in Cancer Therapies: Current Evidence and Future Directions.
Chalif J, Goldstein N, Mehra Y, Spakowicz D, et al · · 2025 · cited 5× · PMID 39856008 · DOI 10.1016/j.hoc.2024.12.005
Verify or expand the search:
- PubMed search for NCT06190847
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Squamous Cell Carcinoma
Currently open trials in the same condition.
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
- NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
- NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
- NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting
Other Anhui Provincial Hospital trials
Trials by the same sponsor.
- NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
- NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
- NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
- NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
- NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06190847 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
- Last refreshed: 5 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06190847.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing